KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $120.6 million.

  • Halozyme Therapeutics' Shares Outstanding (Weighted Average) fell 503.98% to $120.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.6 million, marking a year-over-year decrease of 503.98%. This contributed to the annual value of $126.8 million for FY2024, which is 386.58% down from last year.
  • Halozyme Therapeutics' Shares Outstanding (Weighted Average) amounted to $120.6 million in Q3 2025, which was down 503.98% from $122.3 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $142.5 million in Q2 2021 and a low of $120.6 million during Q3 2025
  • For the 5-year period, Halozyme Therapeutics' Shares Outstanding (Weighted Average) averaged around $132.6 million, with its median value being $133.4 million (2023).
  • Per our database at Business Quant, Halozyme Therapeutics' Shares Outstanding (Weighted Average) soared by 433.1% in 2021 and then crashed by 598.84% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Shares Outstanding (Weighted Average) stood at $140.6 million in 2021, then fell by 2.7% to $136.8 million in 2022, then decreased by 3.59% to $131.9 million in 2023, then decreased by 3.87% to $126.8 million in 2024, then decreased by 4.93% to $120.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $120.6 million in Q3 2025, compared to $122.3 million in Q2 2025 and $123.2 million in Q1 2025.